For Immediate Release:

Contact: Allen & Caron Inc   CLOSURE Medical Corp
  Joe Allen (investors) Len Hall (media) Daniel Pelak, CEO
  (212) 691-8087 (949) 474-4300 Benny Ward, CFO (919) 876-7800


RALEIGH, NC (March 17, 2003) … CLOSURE Medical Corporation (Nasdaq:CLSR), a global leader in medical adhesives, announced the appointment of James F. Buck, 40, to the position of Vice President of Marketing. Mr. Buck will concentrate on expanding the markets in which CLOSURE already participates, as well as identify and pursue additional market and strategic opportunities.

CLOSURE President and CEO, Daniel A. Pelak, commented, “Jim possesses a strong customer-focused approach and broad experience within the medical device industry necessary to strengthen the CLOSURE management team. We look forward to working closely with Jim as we continue to focus on increasing value for our shareholders.”

Mr. Buck has an eleven year history of progressive responsibility at St. Jude Medical, Inc. He has advanced through assignments in marketing research and independent sales and sales management. He has held management positions in business development and marketing. Most recently, Mr. Buck served as the Senior Director, Healthcare Services, a corporate strategic marketing function within St. Jude Medical.

“I am very excited about the tremendous opportunity at CLOSURE,” Buck said. “The Company is an established market leader. With its proprietary medical adhesive technology, intellectual property portfolio and financial resources, I believe there is great potential to leverage the current products and techniques for wound closure and to address potentially new and emerging indications.”

Mr. Buck earned a B.S. in Marketing from Indiana University and an M.B.A. with distinction from Northwestern University’s Kellogg Graduate School of Management.

About CLOSURE Medical Corporation
CLOSURE Medical Corporation is a global leader in the development, manufacture, and commercialization of medical adhesives based on its proprietary medical grade cyanoacrylate technology. CLOSURE's proprietary technology has customized the physical and chemical properties of cyanoacrylates to develop medical adhesive formulations to close and seal topical skin wounds and incisions.

For additional information on CLOSURE Medical visit its website at or visit the "Clients" section of the Allen & Caron website at

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company’s products; the progress of its research and development programs for future products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; the satisfactory conclusion of negotiations with, and dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, filed with the Securities and Exchange Commission. Although the Company believes that the expectations in the forward-looking statements are reasonable, the Company cannot guarantee such results. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.